Skip to main content

Table 1 Baseline characteristics of subgroups taking high-dose, low-dose, or no glucocorticoids at baseline

From: Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

  High-dose glucocorticoids (n = 8) Low-dose glucocorticoids (n = 353) No glucocorticoids (n = 302)
Male 2 (25.0) 189 (53.5) 165 (54.6)
Age, years 61.8 (4.2) 65.5 (10.0) 66.2 (9.6)
Former or current smoker 3 (37.5) 173 (49.0) 162 (53.6)
ILD diagnosis    
 Hypersensitivity pneumonitis 5 (62.5) 96 (27.2) 72 (23.8)
 Autoimmune ILDsa 1 (12.5) 114 (32.3) 55 (18.2)
 iNSIP 0 65 (18.4) 60 (19.9)
 Unclassifiable IIP 2 (25.0) 41 (11.6) 71 (23.5)
 Other ILDsb 0 37 (10.5) 44 (14.6)
FVC, mL 1744 (546) 2287 (696) 2397 (771)
FVC, % predicted 53.8 (6.9) 67.4 (14.9) 71.2 (16.2)
DLco, % predicted 44.4 (9.1) 44.4 (12.6) 48.2 (14.6)
  1. Data are shown as n (%) or mean (SD). Glucocorticoids with oral, intravenous, intravenous bolus, intravenous drip, or intramuscular route of administration. High-dose glucocorticoids: > 20 mg/day prednisone or equivalent
  2. DLco: diffusing capacity of the lung for carbon monoxide, corrected for hemoglobin; FVC: forced vital capacity; IIP: idiopathic interstitial pneumonia; ILD: interstitial lung disease; iNSIP: idiopathic non-specific interstitial pneumonia; MCTD: mixed connective tissue disease; RA: rheumatoid arthritis; SSc: systemic sclerosis
  3. aIncluded RA-ILD, SSc-ILD, MCTD-ILD, plus autoimmune ILDs in the “Other fibrosing ILDs” category of the case report form
  4. bIncluded sarcoidosis, exposure-related ILDs and selected other terms in the “Other fibrosing ILDs” category of the case report form